Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06014762 · ClinicalTrials.gov registry record · Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

A Phase 1 study of High Grade B-Cell Lymphoma and DLBCL, sponsored by Poseida Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
17
Study locations

NCT06014762: Recruiting Phase 1 study of High Grade B-Cell Lymphoma and DLBCL, sponsored by Poseida Therapeutics.

NCT06014762 is a Phase 1 study of High Grade B-Cell Lymphoma and DLBCL that is actively recruiting participants, run by Poseida Therapeutics. The registered enrollment target is 120 participants, above the 58-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (107% higher). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06014762, a Phase 1 study of High Grade B-Cell Lymphoma and DLBCL, is actively recruiting participants, sponsored by Poseida Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
17
Study locations

Study Summary

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Primary Outcome

Rate of DLT's

Conditions Studied

High Grade B-Cell Lymphoma DLBCL Diffuse Large B-Cell Lymphoma, Not Otherwise Specified DLBCL - Diffuse Large B Cell Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Transformed Follicular Lymphoma (tFL) Follicular Lymphoma Grade 3B Dlbcl NOS DLBCL Arising From Follicular Lymphoma DLBCL, Diffused Large B Cell Lymphoma

Interventions

  • DRUG Rimiducid
  • BIOLOGICAL P-CD19CD20-ALLO1

Study Locations (17)

California

  • University of California San Diego - La Jolla
  • Loma Linda University Cancer Center - Loma Linda
  • Cedars-Sinai Medical Center - Los Angeles

Louisiana

  • Our Lady of the Lake Hospital - Baton Rouge
  • Ochsner Clinic Foundation - New Orleans

Florida

  • Advent Health Orlando - Orlando

Indiana

  • Indiana University - Indianapolis

Michigan

  • Wayne State - Karmanos Cancer Institute - Detroit

New York

  • NYU Grossman School of Medicine - New York

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-04-16
Est. Completion 2041-03
Phase Phase 1
Poseida Therapeutics

6 total trials

What NCT06014762 shows while recruiting

NCT06014762 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 58-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (107% higher).

The record links to 10 conditions, with High Grade B-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rimiducid is the first listed.

NCT06014762 lists 17 locations in 14 states (California, Louisiana, Florida).

Frequently Asked Questions

What is clinical trial NCT06014762 about?

NCT06014762 is a clinical study titled "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies". Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

What is the current status of trial NCT06014762?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-04-16. Estimated completion is 2041-03.

What conditions does trial NCT06014762 study?

This clinical trial studies the following conditions: High Grade B-Cell Lymphoma, DLBCL, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, DLBCL - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL).

What interventions are being tested in trial NCT06014762?

The interventions under investigation include: Rimiducid (DRUG), P-CD19CD20-ALLO1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06014762?

This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06014762 being conducted?

This trial has 17 study locations across California, Florida, Indiana, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for High Grade B-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06014762's enrollment target sits among peer trials

120 4th of 25 higher than 22 of 25 other High Grade B-Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other High Grade B-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06014762

Source: ClinicalTrials.gov NCT06014762, the US trial registry maintained by the National Library of Medicine. NCT06014762 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.